M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
Early detection of laryngeal cancer: prominence of miRNA signature as a new tool for clinicians
Hiromichi Kawasaki,Mayra Rachele Zarone,Angela Lombardi,Filippo Ricciardiello,Michele Caraglia,Gabriella Misso +5 more
TL;DR: Their proven stability in systemic circulation and other body fluids, as well as their easy detection and quantization, makes the analysis of miRNA signatures an excellent tool for clinicians as hallmark for cancer classification and diagnosis.
Journal Article
[Evaluation in vitro of the cardiotoxic effects of 5-fluorouracil for the prevention of cardiovascular damage in health workers occupationally exposed].
Monica Lamberti,Michele Caraglia,Silvia Zappavigna,M. Marra,Ritonnaro C,Coppola Ma,Silvio Naviglio,Stefania Porto,Marsella L,Nicola Sannolo +9 more
TL;DR: This experimental study wants to analyze on the H9c2 cardiomyocyte cell model the effects of 5-Fluorouracil, commonly used in hospital realities of the South Italy, for the prevention of the possible cardiovascular damage in workers occupationally exposed.
Journal ArticleDOI
Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study.
Raffaele Addeo,Michele Caraglia,Bruno Vincenzi,Amalia Luce,Liliana Montella,Amerigo Mastella,Salvatore Mazzone,Filippo Ricciardiello,Marco Carraturo,Salvatore Del Prete,Pasquale Sperlongano +10 more
TL;DR: Cetuximab plus radiotherapy appears to be feasible and active in elderly patients unsuitable for cisplatin treatment, and the treatment was supported by a favorable toxicity profile.
Journal ArticleDOI
Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
Raffaele Addeo,Michele Caraglia,M. Serena De Santi,Liliana Montella,Alberto Abbruzzese,Ciro Parlato,Bruno Vincenzi,Marco Carraturo,Vincenzo Faiola,Michele Genovese,Gregorio Cennamo,Salvatore Del Prete +11 more
TL;DR: The online version of the original article can be found under doi:10.1007/s11060-010-0329-z.
Journal ArticleDOI
Mitoxantrone, Etoposide and bleomycin (meb) chemotherapy in non-hodgkins-lymphoma patients non-elegible for standard cyclophosphamide, Doxorubicin, vincristine and prednisone (chop) combination.
Pierosandro Tagliaferri,Elide Matano,A Rea,M. Famiani,Fortunato Ciardiello,Giampaolo Tortora,Montesarchio,Alessandro Morabito,Michele Caraglia,M Delaurentiis,S Deplacido,Giovannella Palmieri,Ar Bianco +12 more
TL;DR: It is demonstrated that MEB chemotherapy possesses good antitumor activity and a manageable toxicity in a prognostically unfavourable subset of lymphoma patients.